Who Paid My Doc Search
Menu
Organisation paid for research Program year 2025 Source: CMS Open Payments

Alliance for Multispecialty

Neither a doctor nor a teaching hospital

Research payments

$1,047,187

205 payments

Through program year 2025, Alliance for Multispecialty is reported as receiving $1,047,187 in research payments, across 205 payments.

By program year

6 rows
Year Kind Amount Payments
2025 Research $279,227 87
2024 Research $100,703 30
2023 Research $548,217 41
2022 Research $44,410 19
2021 Research $53,696 13
2020 Research $20,934 15

Breakdown

Who paid Research payments · program years 2020–2025
  1. Bavarian Nordic A/S $522,265 33 payments
  2. AbbVie, Inc. $397,962 110 payments
  3. Takeda Pharmaceuticals U.S.A., Inc. $63,267 9 payments
  4. Moderna TX, Inc. $34,289 14 payments
  5. Pfizer Inc. $29,404 39 payments
Studies the money was for Research payments · program years 2020–2025
  1. A Phase 3 Trial of the VLP-Based Chikungunya Vaccine PXVX0317 $244,420 15 payments
  2. Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine $175,073 49 payments
  3. Safety and Immunogenicity of CHIKV VLP Vaccine PXVX0317 in Adults 65 Years $125,156 4 payments
  4. Safety and Immunogenicity of CHIKV VLP Vaccine PXVX0317 in Adults 65 Years $94,075 6 payments
  5. A Phase 3, Follow-Up Trial to Evaluate Long-Term Safety and Antibody Persistence, and the Impact of A Booster Dose of A Tetravalent Dengue Vaccine Candidate in Healthy Adolescents and Adults in Areas Non-Endemic for Dengue $63,267 9 payments
  6. A Phase 3 Trial of the VLP-Based Chikungunya Vaccine PXVX0317 $58,613 8 payments
  7. M23-714 - Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine $43,329 9 payments
  8. AGN-151607-DP for the Preventive Treatment of Chronic Migraine in Adults: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase 2 Study (the PURSUE Study) $38,000 2 payments
  9. A Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age $28,555 10 payments
  10. Long-term Extension Study to Assess Safety and Tolerability of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17) $23,284 9 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record